I-Cannabidiol (CBD)

-Delile

• Cishe iyasebenza ...
• Ubufakazi obanele bokukala ukusebenza kwe ...
• Ukuqapha okukhethekile nezixwayiso:

I-Cannabidiol iyikhemikhali esitshalweni se-Cannabis sativa, esaziwa nangokuthi insangu noma i-hemp. Ngaphezulu kwamakhemikhali angama-80, aziwa ngama-cannabinoids, akhonjwe esitshalweni seCannabis sativa. Ngenkathi i-delta-9-tetrahydrocannabinol (iTHC) iyisithako esiyinhloko sentsangu, i-cannabidiol nayo itholakala ku-hemp, equkethe amanani amancane kakhulu we-THC.

Ukudluliswa koMthethosivivinywa weFama i-2018 wakwenza kwaba semthethweni ukuthengisa imikhiqizo ye-hemp ne-hemp e-U.S. Kodwa lokho akusho ukuthi yonke imikhiqizo etholakala nge-hemp ye-cannabidiol isemthethweni. Njengoba i-cannabidiol ifundwe njengomuthi omusha, ayikwazi ukufakwa ngokusemthethweni ekudleni noma kwizithasiselo zokudla. Futhi, i-cannabidiol ayikwazi ukufakwa emikhiqizweni emakethwa ngezimangalo zokwelapha. ICannabidiol ingafakwa kuphela kwimikhiqizo "yezimonyo" futhi kuphela uma iqukethe ngaphansi kuka-0.3% THC. Kepha kusekhona imikhiqizo enelebula njengezithako zokudla emakethe equkethe i-cannabidiol. Inani le-cannabidiol eliqukethwe kule mikhiqizo alihlali libikwa ngokunembile kwilebula yomkhiqizo.

I-Cannabidiol ijwayele ukusetshenziselwa ukugula (isithuthwane). Ibuye isetshenziselwe ukukhathazeka, ubuhlungu, ukuphazamiseka kwemisipha okubizwa nge-dystonia, isifo se-Parkinson, isifo se-Crohn, nezinye izimo eziningi, kepha abukho ubufakazi obuhle besayensi bokusekela lokhu kusetshenziswa.

Imibhalo Yemvelo Yemininingwane Ephelele ukukala ukusebenza ngokuncike ebufakazini besayensi ngokwesilinganiso esilandelayo: Okusebenzayo, Okungenzeka Kusebenze, Okungenzeka Kusebenze, Okungenzeka Kungasebenzi, Cishe Okungaphumeleli, Ukungasebenzi, Nobufakazi Obunganele Bokulinganisa.

Izilinganiso zokusebenza ze I-CANNABIDIOL (CBD) zimi kanje:

Cishe iyasebenza ...

• Isifo sokuquleka (isithuthwane). Umkhiqizo othile we-cannabidiol (i-Epidiolex, i-GW Pharmaceuticals) ukhonjisiwe ukunciphisa ukubanjwa kwabantu abadala nezingane ezinezimo ezahlukahlukene ezixhumene nokuquleka. Lo mkhiqizo umuthi kadokotela wokwelapha ukuquleka okubangelwa i-Dravet syndrome, i-Lennox-Gastaut syndrome, noma i-tuberous sclerosis complex. Kubuye kwakhonjiswa ukunciphisa ukwehliswa kwabantu abane-Sturge-Weber syndrome, i-febrile-related-epilepsy syndrome (i-FIRES), kanye nokuphazamiseka okuthile kwezofuzo okubangela i-encephalopathy yesithuthwane. Kodwa akuvunyelwe ukwelapha lezi ezinye izinhlobo zokubamba. Lo mkhiqizo uvame ukuthathwa uhlanganiswe nemithi ejwayelekile yokulwa nokuquleka. Eminye imikhiqizo ye-cannabidiol eyenziwe elebhu nayo ifundelwa isifo sokuwa. Kepha ucwaningo lukhawulelwe, futhi awukho nowodwa wale mikhiqizo ovunyelwe njengemithi kadokotela.

Ubufakazi obanele bokukala ukusebenza kwe ...

• Uhlobo lwesifo samathumbu esivuthayo (isifo seCrohn). Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-cannabidiol akukunciphisi ukusebenza kwezifo kubantu abadala abanesifo seCrohn.
• Isifo sikashukela. Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-cannabidiol akukuthuthukisi abantu abadala abalawula i-glucose egazini abane-type 2 diabetes.
• Ukuphazamiseka kokuhamba okuphawulwe ngokuncipha kwemisipha okungazibandakanyi (i-dystonia). Akucaci ukuthi i-cannabidiol iyazuzisa yini i-dystonia.
• Isimo esizuzwe njengefa esimakwe ukukhubazeka kokufunda (i-fragile- X syndrome). Ucwaningo lwakuqala luphakamisa ukuthi ukusebenzisa ijeli ye-cannabidiol kunganciphisa ukukhathazeka futhi kuthuthukise indlela yokuziphatha ezinganeni ezine-X syndrome ebuthaka.
• Isimo lapho ukufakelwa kabusha kuhlasela umzimba (isifo se-graft-versus-host noma i-GVHD). Isifo se-Graft-versus-host siyinkinga engenzeka ngemuva kokufakelwa komnkantsha wethambo. Ucwaningo lwakuqala luthole ukuthi ukuthatha i-cannabidiol nsuku zonke ukuqala ezinsukwini eziyi-7 ngaphambi kokufakelwa komnkantsha wethambo nokuqhubeka izinsuku ezingama-30 ngemuva kokufakelwa kungandisa isikhathi esithathayo kumuntu ukwenza i-GVHD.
• Isifo sobuchopho esizuze njengefa esithinta ukunyakaza, imizwa nokucabanga (Isifo sikaHuntington). Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-cannabidiol nsuku zonke akuzithuthukisi izimpawu zesifo sikaHuntington.
• I-Multiple sclerosis (MS). Ucwaningo lwakuqala luphakamisa ukuthi ukusebenzisa i-cannabidiol spray ngaphansi kolimi kungathuthukisa ubuhlungu nokuqina kwemisipha kubantu abane-MS.
• Ukuhoxa kwi-heroin, morphine, nezinye izidakamizwa ze-opioid. Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-cannabidiol izinsuku ezintathu kunganciphisa izifiso nokukhathazeka kubantu abanenkinga yokusebenzisa i-heroin.
• Isifo se-Parkinson. Ucwaningo lwakuqala lukhombisa ukuthi i-cannabidiol inganciphisa ukukhathazeka nezimpawu zengqondo kubantu abanesifo sikaParkinson.
• Ischizophrenia. Ucwaningo lokuqala lubonisa ukuthi ukuthatha i-cannabidiol kuthuthukisa izimpawu nokuphila kahle kubantu abane-schizophrenia.
• Ukuyeka ukubhema. Ucwaningo lwakuqala luphakamisa ukuthi ukuhogela i-cannabidiol nge-inhaler isonto elilodwa kunganciphisa isibalo sogwayi ababhenywa ababhemayo abazama ukuyeka.
• Uhlobo lokukhathazeka olubhalwe ukwesaba kwezinye noma kuzo zonke izilungiselelo zomphakathi (ukuphazamiseka kokukhathazeka komphakathi). Ucwaningo lwakuqala lukhombisa ukuthi i-cannabidiol ingahle ithuthukise ukukhathazeka kubantu abanalesi sifo. Kodwa akucaci ukuthi kuyasiza yini ukunciphisa ukukhathazeka ngesikhathi sokukhuluma phambi kwabantu.
• Iqembu lezimo ezibuhlungu ezithinta ukuhlangana komhlathi nemisipha (izifo ze-temporomandibular noma i-TMD). Ucwaningo lwakuqala lukhombisa ukuthi ukusebenzisa uwoyela oqukethe i-cannabidiol esikhunjeni kunganciphisa ubuhlungu kubantu abane-TMD.
• Ukulimala kwemithambo ezandleni nasezinyaweni (i-peripheral neuropathy).
• Ukuphazamiseka kwe-bipolar.
• Ukuqwasha.
• Ezinye izimo.

Kudingeka ubufakazi obuningi ukukala ukusebenza kwe-cannabidiol kulokhu kusetshenziswa.

I-Cannabidiol inemiphumela ebuchosheni. Imbangela ngqo yale miphumela ayicaci. Kodwa-ke, i-cannabidiol ibonakala ivimbela ukuwohloka kwekhemikhali ebuchosheni ethinta izinhlungu, imizwa nokusebenza kwengqondo. Ukuvimbela ukuwohloka kwaleli khemikhali nokwandisa amazinga alo egazini kubonakala kunciphisa izimpawu zengqondo ezihambisana nezimo ezifana ne-schizophrenia. ICannabidiol ingahle futhi ivimbele eminye yemiphumela yokusebenza kwengqondo ye-delta-9-tetrahydrocannabinol (THC). Futhi, i-cannabidiol ibonakala inciphisa ubuhlungu nokukhathazeka.

Lapho ithathwa ngomlomo: ICannabidiol OKUNGENZEKA UKUPHEPHA lapho ithathwa ngomlomo noma ifuthwe ngaphansi kolimi ngokufanele. I-Cannabidiol ngemithamo efinyelela ku-300 mg nsuku zonke ithathwe ngomlomo ngokuphepha izinyanga ezi-6. Imithamo ephakeme ye-1200-1500 mg nsuku zonke ithathwe ngomlomo ngokuphepha kuze kube amasonto ama-4. Umkhiqizo kadokotela we-cannabidiol (i-Epidiolex) uvunyelwe ukuthi uthathwe ngomlomo ngemithamo efinyelela kuma-25 mg / kg nsuku zonke. Izifutho zeCannabidiol ezisetshenziswa ngaphansi kolimi zisetshenziswe ngemithamo ye-2.5 mg amasonto angafika kwamabili.

Eminye imiphumela emibi ebikiwe ye-cannabidiol ifaka phakathi umlomo owomile, umfutho ophansi wegazi, ukukhanyisa okukhanyayo, kanye nokozela. Izimpawu zokulimala kwesibindi nazo zibikiwe kwezinye iziguli, kepha lokhu akuvamile.

Lapho isetshenziswa esikhunjeni: Alukho ulwazi olwanele oluthembekile lokwazi ukuthi i-cannabidiol iphephile yini noma yini imiphumela emibi engaba yiyo.

Ukuqapha okukhethekile nezixwayiso:

Ukukhulelwa nokuncelisa ibele: ICannabidiol MHLAWUMBI ANGIPHEPHILE ukusebenzisa uma ukhulelwe noma uncelisa ibele. Imikhiqizo yeCannabidiol ingangcoliswa nezinye izithako ezingaba yingozi kumntwana noma usana. Hlala ohlangothini oluphephile futhi ugweme ukusetshenziswa.

Izingane: Umkhiqizo kadokotela we-cannabidiol (i-Epidiolex) ngu OKUNGENZEKA UKUPHEPHA lapho ithathwa ngomlomo ngemithamo efinyelela ku-25 mg / kg nsuku zonke. Lo mkhiqizo uvunyelwe ukusetshenziswa ezinganeni ezithile ezinonyaka owodwa nangaphezulu.

Isifo sesibindi: Abantu abanesifo sesibindi bangadinga ukusebenzisa imithamo ephansi ye-cannabidiol uma kuqhathaniswa neziguli ezinempilo.

Isifo se-Parkinson: Olunye ucwaningo lwakuqala lukhombisa ukuthi ukuthatha imithamo ephezulu ye-cannabidiol kungenza ukunyakaza kwemisipha nokuzamazama kube kubi kakhulu kubantu abanesifo i-Parkinson.

Maphakathi

Qaphela ngale nhlanganisela.

I-Brivaracetam (Briviact)

I-Brivaracetam iyashintshwa futhi yephulwe ngumzimba. I-Cannabidiol inganciphisa ukuthi umzimba wephula kanjani i-brivaracetam ngokushesha. Lokhu kungakhuphula amazinga we-brivaracetam emzimbeni.

I-Carbamazepine (Tegretol)

ICarbamazepine iyashintshwa futhi yephulwe ngumzimba. I-Cannabidiol inganciphisa ukuthi umzimba wephula kanjani ngokushesha i-carbamazepine. Lokhu kungakhuphula amazinga e-carbamazepine emzimbeni futhi kukhulise imiphumela yawo emibi.

I-Clobazam (Onfi)

I-Clobazam iyashintshwa futhi yephulwe yisibindi. I-Cannabidiol inganciphisa ukuthi isibindi sidiliza kanjani i-clobazam ngokushesha. Lokhu kungakhuphula imiphumela kanye nemiphumela emibi ye-clobazam.

I-Eslicarbazepine (Aptiom)

I-Eslicarbazepine iyashintshwa futhi yephulwe ngumzimba. I-Cannabidiol ingahle yehle ukuthi umzimba wehla ngokushesha kangakanani i-eslicarbazepine. Lokhu kungakhuphula amazinga e-eslicarbazepine emzimbeni ngenani elincane.

I-Everolimus (iZostress)

I-Everolimus iyashintshwa futhi yephulwe ngumzimba. I-Cannabidiol inganciphisa ukuthi umzimba wehla kanjani ngokushesha i-everolimus. Lokhu kungakhuphula amazinga e-everolimus emzimbeni.

ILithium

Ukuthatha imithamo ephakeme ye-cannabidiol kungakhuphula amazinga e-lithium. Lokhu kungakhuphula ubungozi be-lithium toxicity.

Imithi ishintshwe yisibindi (iziqhekeza zeCytochrome P450 1A1 (CYP1A1))

Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol ingahle yehlise ukuthi isibindi sehla ngokushesha kanjani eminye imithi. Ngokwethiyori, ukusebenzisa i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yeminye imithi. Ngaphambi kokusebenzisa i-cannabidiol, khuluma nomhlinzeki wakho wezokunakekelwa kwezempilo uma uthatha noma yimiphi imithi eshintshwa yisibindi.

Eminye imithi eshintshwe yisibindi ifaka i-chlorzoxazone (i-Lorzone) ne-theophylline (Theo-Dur, eminye).

Imithi ishintshwe yisibindi (iziqhekeza zeCytochrome P450 1A2 (CYP1A2))

Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol ingahle yehlise ukuthi isibindi sehla ngokushesha kanjani eminye imithi. Ngokwethiyori, ukusebenzisa i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yeminye imithi. Ngaphambi kokusebenzisa i-cannabidiol, khuluma nomhlinzeki wakho wezokunakekelwa kwezempilo uma uthatha noma yimiphi imithi eshintshwa yisibindi.

Eminye imishanguzo eshintshwe yisibindi ihlanganisa i-amitriptyline (Elavil), i-haloperidol (i-Haldol), i-ondansetron (i-Zofran), i-propranolol (i-Inderal), i-theophylline (i-Theo-Dur, abanye), i-verapamil (i-Calan, i-Isoptin, abanye), neminye.

Imithi ishintshwe yisibindi (iziqhekeza zeCytochrome P450 1B1 (CYP1B1))

Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol ingahle yehlise ukuthi isibindi sehla ngokushesha kanjani eminye imithi. Ngokwethiyori, ukusebenzisa i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yeminye imithi. Ngaphambi kokusebenzisa i-cannabidiol, khuluma nomhlinzeki wakho wezokunakekelwa kwezempilo uma uthatha noma yimiphi imithi eshintshwa yisibindi.

Eminye imithi eshintshwe yisibindi ifaka i-theophylline (Theo-Dur, eminye), i-omeprazole (Prilosec, i-Omesec), i-clozapine (i-Clozaril, i-FazaClo), i-progesterone (i-Prometrium, abanye), i-lansoprazole (i-Prevacid), i-flutamide (i-Eulexin), i-oxaliplatin (i-Eloxatin) ), i-erlotinib (iTarceva), ne-caffeine.

Imithi ishintshwe yisibindi (iziqhekeza zeCytochrome P450 2A6 (CYP2A6))

Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol ingahle yehlise ukuthi isibindi sehla ngokushesha kanjani eminye imithi. Ngokwethiyori, ukusebenzisa i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yeminye imithi. Ngaphambi kokusebenzisa i-cannabidiol, khuluma nomhlinzeki wakho wezokunakekelwa kwezempilo uma uthatha noma yimiphi imithi eshintshwa yisibindi.

Eminye imishanguzo eshintshwe yisibindi ifaka i-nicotine, i-chlormethiazole (i-Heminevrin), i-coumarin, i-methoxyflurane (i-Penthrox), i-halothane (i-Fluothane), i-valproic acid (i-Depacon), i-disulfiram (i-Antabuse), neminye.

Imithi ishintshwe yisibindi (iziqhekeza zeCytochrome P450 2B6 (CYP2B6))

Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol ingahle yehlise ukuthi isibindi sehla ngokushesha kanjani eminye imithi. Ngokwethiyori, ukusebenzisa i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yeminye imithi. Ngaphambi kokusebenzisa i-cannabidiol, khuluma nomhlinzeki wakho wezokunakekelwa kwezempilo uma uthatha noma yimiphi imithi eshintshwa yisibindi.

Eminye imithi eshintshwe yisibindi ifaka phakathi i-ketamine (Ketalar), i-phenobarbital, i-orphenadrine (i-Norflex), i-secobarbital (i-Seconal), ne-dexamethasone (i-Decadron).

Imithi ishintshwe yisibindi (iziqhekeza zeCytochrome P450 2C19 (CYP2C19))

Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol ingahle yehlise ukuthi isibindi sehla ngokushesha kanjani eminye imithi. Ngokwethiyori, ukusebenzisa i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yeminye imithi. Ngaphambi kokusebenzisa i-cannabidiol, khuluma nomhlinzeki wakho wezokunakekelwa kwezempilo uma uthatha noma yimiphi imithi eshintshwa yisibindi.

Eminye imishanguzo eguqulwe isibindi ifaka phakathi ama-proton pump inhibitors afaka i-omeprazole (Prilosec), i-lansoprazole (i-Prevacid), ne-pantoprazole (i-Protonix); diazepam (Valium); i-carisoprodol (iSoma); i-nelfinavir (i-Viracept); nabanye.

Imithi ishintshwe yisibindi (iziqhekeza zeCytochrome P450 2C8 (CYP2C8))

Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol ingahle yehlise ukuthi isibindi sehla ngokushesha kanjani eminye imithi. Ngokwethiyori, ukusebenzisa i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yeminye imithi. Ngaphambi kokusebenzisa i-cannabidiol, khuluma nomhlinzeki wakho wezokunakekelwa kwezempilo uma uthatha noma yimiphi imithi eshintshwa yisibindi.
Eminye imithi eshintshwe yisibindi ihlanganisa i-amiodarone (Cordarone), i-carbamazepine (Tegretol), i-chloroquine (i-Aralen), i-diclofenac (i-Voltaren), i-paclitaxel (i-Taxol), i-repaglinide (i-Prandin) neminye.

Imithi ishintshwe yisibindi (iziqhekeza zeCytochrome P450 2C9 (CYP2C9))

Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol ingahle yehlise ukuthi isibindi sehla ngokushesha kanjani eminye imithi. Ngokwethiyori, ukusebenzisa i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yeminye imithi. Ngaphambi kokusebenzisa i-cannabidiol, khuluma nomhlinzeki wakho wezokunakekelwa kwezempilo uma uthatha noma yimiphi imithi eshintshwa yisibindi.

Eminye imishanguzo eguqulwe isibindi ifaka izidakamizwa ezingezona ukuvuvukala (ama-NSAID) ezinjenge-diclofenac (Cataflam, Voltaren), ibuprofen (Motrin), meloxicam (Mobic), piroxicam (Feldene), ne-celecoxib (Celebrex); i-amitriptyline (u-Elavil); i-warfarin (i-Coumadin); i-glipizide (iGlucotrol); losartan (Cozaar); nabanye.

Imithi ishintshwe yisibindi (iziqhekeza zeCytochrome P450 2D6 (CYP2D6))

Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol inganciphisa ukuthi isibindi siqeda kanjani imithi ethile ngokushesha. Ngokwethiyori, ukusebenzisa i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yeminye imithi. Ngaphambi kokusebenzisa i-cannabidiol, khuluma nomhlinzeki wakho wezokunakekelwa kwezempilo uma uthatha noma yimiphi imithi eshintshwa yisibindi.

Eminye imishanguzo eguqulwe isibindi ifaka i-amitriptyline (Elavil), i-codeine, i-desipramine (i-Norpramin), i-flecainide (i-Tambocor), i-haloperidol (i-Haldol), i-imipramine (i-Tofranil), i-metoprolol (i-Lopressor, i-Toprol XL), i-ondansetron (i-Zofran), i-paroxetine (i-Paxiletine) ), risperidone (Risperdal), tramadol (Ultram), venlafaxine (Effexor), nabanye.

Imithi ishintshwe yisibindi (iziqhekeza zeCytochrome P450 3A4 (CYP3A4))

Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol inganciphisa ukuthi isibindi siqeda kanjani imithi ethile ngokushesha. Ngokwethiyori, ukusebenzisa i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yeminye imithi. Ngaphambi kokusebenzisa i-cannabidiol, khuluma nomhlinzeki wakho wezokunakekelwa kwezempilo uma uthatha noma yimiphi imithi eshintshwa yisibindi.

Eminye imithi eshintshwe yisibindi ihlanganisa i-alprazolam (Xanax), i-amlodipine (i-Norvasc), i-clarithromycin (i-Biaxin), i-cyclosporine (iSandimmune), i-erythromycin, i-lovastatin (i-Mevacor), i-ketoconazole (i-Nizoral), i-itraconazole (i-Sporanox), i-fexofenadine (Halcion), verapamil (Calan, Isoptin) nabanye abaningi.

Imithi ishintshwe yisibindi (iziqhekeza zeCytochrome P450 3A5 (CYP3A5))

Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol inganciphisa ukuthi isibindi siqeda kanjani imithi ethile ngokushesha. Ngokwethiyori, ukusebenzisa i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yeminye imithi. Ngaphambi kokusebenzisa i-cannabidiol, khuluma nomhlinzeki wakho wezokunakekelwa kwezempilo uma uthatha noma yimiphi imithi eshintshwa yisibindi.

Eminye imishanguzo eshintshwe yisibindi ifaka phakathi i-testosterone, progesterone (Endometrin, Prometrium), nifedipine (Adalat CC, Procardia XL), cyclosporine (Sandimmune), neminye.

Imithi eshintshwe yisibindi (Izidakamizwa ezinesibindi)

Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol inganciphisa ukuthi isibindi siqeda kanjani imithi ethile ngokushesha. Ukuthatha i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yale mithi.
Eminye yale mithi eshintshwe yisibindi ihlanganisa i-acetaminophen (iTylenol, eminye) ne-oxazepam (Serax), haloperidol (Haldol), lamotrigine (Lamictal), morphine (MS Contin, Roxanol), zidovudine (AZT, Retrovir), neminye.

Imithi eyehlisa ukuwohloka kweminye imithi ngesibindi (Cytochrome P450 2C19 (CYP2C19) inhibitors)

I-Cannabidiol idilizwe yisibindi. Eminye imishanguzo inganciphisa ukuthi isibindi sehla ngokushesha kanjani i-cannabidiol. Ukuthatha i-cannabidiol kanye nale mithi kungakhuphula imiphumela kanye nemiphumela emibi ye-cannabidiol.
Eminye imishanguzo enganciphisa ukonakala kwe-cannabidiol esibindini ifaka i-cimetidine (Tagamet), i-fluvoxamine (i-Luvox), i-omeprazole (i-Prilosec); ticlopidine (Ticlid), topiramate (Topamax), nabanye.

Imithi eyehlisa ukuwohloka kweminye imithi esibindini (i-Cytochrome P450 3A4 (CYP3A4) inhibitors)

I-Cannabidiol idilizwe yisibindi. Eminye imishanguzo inganciphisa ukuthi isibindi sehla ngokushesha kanjani i-cannabidiol. Ukuthatha i-cannabidiol kanye nale mithi kungakhuphula imiphumela kanye nemiphumela emibi ye-cannabidiol.
Eminye imishanguzo enganciphisa ukuthi isibindi sehla ngokushesha kanjani i-cannabidiol ifaka i-amiodarone (Cordarone), i-clarithromycin (i-Biaxin), i-diltiazem (i-Cardizem), i-erythromycin (i-E-mycin, i-Erythrocin), i-indinavir (i-Crixivan), i-ritonavir (i-Norvir), i-saquinavir (i-Fortovase) , Invirase), nabanye abaningi.

Imithi ekhulisa ukuwohloka kweminye imithi ngesibindi (i-Cytochrome P450 3A4 (CYP3A4) inducers)

I-Cannabidiol idilizwe yisibindi. Eminye imishanguzo ingakhuphula ukuthi isibindi sehla ngokushesha kanjani i-cannabidiol. Ukuthatha i-cannabidiol kanye nale mithi kunganciphisa imiphumela ye-cannabidiol.
Eminye yale mithi ifaka i-carbamazepine (Tegretol), phenobarbital, phenytoin (Dilantin), rifampin, rifabutin (Mycobutin), neminye.

Imithi ekhulisa ukuwohloka kweminye imithi ngesibindi (i-Cytochrome P450 2C19 (CYP2C19) inducers)

I-Cannabidiol idilizwe yisibindi. Eminye imishanguzo ingakhuphula ukuthi isibindi sehla ngokushesha kanjani i-cannabidiol. Ukuthatha i-cannabidiol kanye nale mithi kunganciphisa imiphumela ye-cannabidiol.
Eminye imithi engakhuphula ukuwohloka kwe-cannabidiol esibindini ifaka i-carbamazepine (Tegretol), i-prednisone (i-Deltasone), ne-rifampin (i-Rifadin, i-Rimactane).

I-Methadone (Dolophine)

IMethadone idilizwe yisibindi. I-Cannabidiol ingahle yehlise ukuthi isibindi sidiliza kanjani i-methadone ngokushesha. Ukuthatha i-cannabidiol kanye ne-methadone kungakhuphula imiphumela kanye nemiphumela emibi ye-methadone.

I-Rufinamide (Banzel)

URufinamide uyashintshwa futhi wephulwe ngumzimba. I-Cannabidiol inganciphisa ukuthi umzimba wephula kanjani i-rufinamide ngokushesha okukhulu. Lokhu kungakhuphula amazinga e-rufinamide emzimbeni ngenani elincane.

Imithi yokudambisa (i-CNS depressants)

I-Cannabidiol ingadala ubuthongo nokulala. Imithi ebanga ubuthongo ibizwa ngokuthi yimithi yokuthambisa. Ukuthatha i-cannabidiol kanye nemithi yokwelapha kungadala ukulala kakhulu.

Eminye imishanguzo yokuthambisa ibandakanya i-benzodiazepines, i-pentobarbital (i-Nembutal), i-phenobarbital (i-Luminal), i-secobarbital (i-Seconal), i-thiopental (i-Pentothal), i-fentanyl (i-Duragesic, i-Sublimaze), i-morphine, i-propofol (i-Diprivan), neminye.

I-Sirolimus (Rapamune)

I-Sirolimus iyashintshwa futhi yephulwe ngumzimba. I-Cannabidiol inganciphisa ukuthi umzimba wehla ngokushesha kanjani i-sirolimus. Lokhu kungakhuphula amazinga e-sirolimus emzimbeni.

I-Stiripentol (Diacomit)

I-Stiripentol iyashintshwa futhi yephulwe ngumzimba. I-Cannabidiol inganciphisa ukuthi umzimba wephula ngokushesha kanjani i-stiripentol. Lokhu kungakhuphula amazinga e-stiripentol emzimbeni futhi kwandise imiphumela yawo emibi.

I-Tacrolimus (Prograf)

I-tacrolimus iyashintshwa futhi yephulwe ngumzimba. I-Cannabidiol inganciphisa ukuthi umzimba weqa kanjani ngokushesha i-tacrolimus. Lokhu kungakhuphula amazinga we-tacrolimus emzimbeni.

I-Topiramate (Tompamax)

I-Topiramate ishintshwa futhi yephulwe ngumzimba. I-Cannabidiol inganciphisa ukuthi umzimba wephula kanjani ngokushesha i-topiramate. Lokhu kungakhuphula amazinga we-topiramate emzimbeni ngenani elincane.

I-Valproate

I-Valproic acid ingadala ukulimala kwesibindi. Ukuthatha i-cannabidiol nge-valproic acid kungandisa amathuba okulimala kwesibindi. I-Cannabidiol kanye / noma i-valproic acid ingadinga ukumiswa, noma umthamo ungadinga ukwehliswa.

I-Warfarin

I-Cannabidiol ingakhuphula amazinga e-warfarin, angakhuphula ingozi yokuphuma kwegazi. I-Cannabidiol kanye / noma i-warfarin ingadinga ukumiswa, noma umthamo ungadinga ukwehliswa.

Zonisamide

I-Zonisamide iyashintshwa futhi yephulwe ngumzimba. I-Cannabidiol inganciphisa ukuthi umzimba wephula kanjani ngokushesha i-zonisamide. Lokhu kungakhuphula amazinga we-zonisamide emzimbeni ngenani elincane.

Amakhambi kanye nezithasiselo ezinezakhiwo zokuthambisa

I-Cannabidiol ingadala ukulala noma ukozela. Ukuyisebenzisa kanye namanye amakhambi nezithako ezinomphumela ofanayo kungadala ukulala okuningi. Amanye alawa makhambi nezithasiselo afaka i-calamus, i-poppy yaseCalifornia, i-catnip, i-hops, i-dogwood yaseJamaican, i-kava, i-L-tryptophan, i-melatonin, i-sage, i-SAMe, i-wort yaseSt.

Utshwala (i-Ethanol)

Ukuthatha i-cannabidiol ngotshwala kwandisa inani le-cannabidiol elimuncwa umzimba. Lokhu kungakhuphula imiphumela nemiphumela emibi ye-cannabidiol.

Amafutha nokudla okuqukethe amafutha

Ukuthatha i-cannabidiol ngesidlo esinamafutha amaningi noma okungenani kuqukethe amafutha, kwandisa inani le-cannabidiol elimuncwa umzimba. Lokhu kungakhuphula imiphumela nemiphumela emibi ye-cannabidiol.

Ubisi

Ukuthatha i-cannabidiol ngobisi kwandisa inani le-cannabidiol elimuncwa umzimba. Lokhu kungakhuphula imiphumela emibi ye-cannabidiol.

Imithamo elandelayo ifundwe ocwaningweni lwesayensi:

ABADALA

NGOMLOMO:

• Isifo sokuwa: Kusetshenziswe umkhiqizo kadokotela we-cannabidiol (i-Epidiolex). Umthamo onconywayo wokuqala weLennox-Gastaut syndrome ne-Dravet syndrome ngu-2.5 mg / kg kabili ngosuku (5 mg / kg / ngosuku). Ngemuva kwesonto elilodwa umthamo ungakhuphukela ku-5 mg / kg kabili ngosuku (10 mg / kg / ngosuku). Uma umuntu engaphenduli kulo mthamo, isilinganiso esiphakanyisiwe ngu-10 mg / kg kabili ngosuku (20 mg / kg / ngosuku). Umthamo onconywayo wokuqala we-tuberous sclerosis complex ngu-2.5 mg / kg kabili ngosuku (5 mg / kg / ngosuku). Lokhu kungakhuphuka ngezikhathi zamasonto onke uma kunesidingo, kuze kufike ku-12.5 mg / kg kabili ngosuku (25 mg / kg / ngosuku). Abukho ubufakazi obuqinile besayensi bokuthi imikhiqizo ye-cannabidiol engabhalisiwe iyazuzisa ngesifo sokuwa.

IZINGANE

NGOMLOMO:

• Isifo sokuwa: Kusetshenziswe umkhiqizo kadokotela we-cannabidiol (i-Epidiolex). Umthamo onconywayo wokuqala weLennox-Gastaut syndrome ne-Dravet syndrome ngu-2.5 mg / kg kabili ngosuku (5 mg / kg / ngosuku). Ngemuva kwesonto elilodwa umthamo ungakhuphukela ku-5 mg / kg kabili ngosuku (10 mg / kg / ngosuku). Uma umuntu engaphenduli kulo mthamo, ubukhulu obuphakanyisiwe ngu-10 mg / kg kabili ngosuku (20 mg / kg / ngosuku). Umthamo onconywayo wokuqala we-tuberous sclerosis complex ngu-2.5 mg / kg kabili ngosuku (5 mg / kg / ngosuku). Lokhu kungakhuphuka ngezikhathi zamasonto onke uma kunesidingo, kuze kufike ku-12.5 mg / kg kabili ngosuku (25 mg / kg / ngosuku). Abukho ubufakazi obuqinile besayensi bokuthi imikhiqizo ye-cannabidiol engabhalisiwe iyazuzisa ngesifo sokuwa.

2 - [(1R, 6R) -3-Methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl] -5-pentylbenzene-1,3-diol, CBD.

Ukuze ufunde kabanzi ngokuthi le ndatshana ibhalwe kanjani, sicela ubheke ifayela le- Imibhalo Yemvelo Yemininingwane Ephelele indlela.

1. USingh RK, uDillon B, uTatum DA, uVan Poppel KC, uBonthius DJ. Ukusebenzisana Kwezidakamizwa Nezidakamizwa Phakathi KweCannabidiol neLithium. Ingane Neurol Ivulekile. 2020; 7: 2329048X20947896. Buka okungaqondakali.
2. Izgelov D, Davidson E, Barasch D, Regev A, Domb AJ, Hoffman A. Pharmacokinetic uphenyo lokwenziwa kwe-cannabidiol ukwenziwa ngomlomo kumavolontiya anempilo. I-Eur J Pharm Biopharm. 2020; 154: 108-115. Buka okungaqondakali.
3. UGurley BJ, uMurphy TP, uGul W, uWalker LA, u-ElSohly M. Okuqukethwe kuqhathaniswa nezimangalo zelebula eCannabidiol (CBD) -Iqukethe Imikhiqizo Etholakale Ezitolo Zezentengiselwano eSifundazweni SaseMississippi. J Ukudla Suppl. 2020; 17: 599-607. Buka okungaqondakali.
4. UMcGuire P, uRobson P, uCubala WJ, et al. I-Cannabidiol (i-CBD) njenge-Adjunctive Therapy eSchizophrenia: Isivivinyo Esilawulwa Ngokungahleliwe Esilawulwa Ngezikhathi Eziningi. Am J Psychiatry. 2018; 175: 225-231. Buka okungaqondakali.
5. Ukulungiswa komthamo weCortopassi J. Warfarin kuyadingeka ngemuva kokuqala kwe-cannabidiol kanye ne-titration. NginguJ J Health Syst Pharm. 2020; 77: 1846-1851. Buka okungaqondakali.
6. IBloomfield MAP, iGreen SF, uHindocha C, et al. Imiphumela ye-cannabidiol ebukhali ekugelezeni kwegazi lobuchopho nobudlelwano bayo nenkumbulo: Ucwaningo lwe-arterial spin lokufaka uphawu lokucabanga ngemagnificent resonance. J I-Psychopharmacol. 2020; 34: 981-989. Buka okungaqondakali.
7. UWang GS, uBourne DWA, uKlawitter J, et al. Ukuchithwa kwe-Oral Cannabidiol-Rich Cannabis Extracts ezinganeni ezine-Epilepsy. Umtholampilo Pharmacokinet. 2020. Buka okungaqondakali.
8. UTaylor L, Crockett J, Tayo B, uChecketts D, uSommerville K. Ukuhoxiswa okungazelelwe kwe-cannabidiol (CBD): Isivivinyo esingahleliwe. Isifo sokuwa Behav. 2020; 104 (Pt A): 106938. Buka okungaqondakali.
9. UMcNamara NA, uDang LT, uStrurza J, et al. I-Thrombocytopenia ezigulini zezingane ku-cannabidiol kanye ne-valproic acid efanayo. Isifo sokuwa. 2020. Buka okungaqondakali.
10. URianprakaisang T, uGerona R, uHendrickson RG. Uwoyela wezohwebo we-cannabidiol ungcoliswe ne-synthetic cannabinoid AB-FUBINACA enikezwe isiguli sezingane. IClin Toxicol (Phila). 2020; 58: 215-216. Buka okungaqondakali.
11. UMorrison G, Crockett J, Blakey G, Sommerville K. Isigaba 1, i-Open-Label, Isivivinyo se-Pharmacokinetic Sokuphenya Ukusebenzisana Okungenzeka Ngezidakamizwa Phakathi Kwezinhlayiya zeClobazam, iStiripentol, noma iValproate neCannabidiol ezifundweni ezinempilo. I-Clin Pharmacol Izidakamizwa. 2019; 8: 1009-1031. Buka okungaqondakali.
12. UMiller I, uScheffer IE, uGunning B, et al. Umphumela Oguqula Umthamo we-Adjunctive Oral Cannabidiol vs Placebo ku-Convulsive Seizure Frequency e-Dravet Syndrome: Isivivinyo Somtholampilo Esingahleliwe. I-JAMA Neurol. 2020; 77: 613-621. Buka okungaqondakali.
13. ILattanzi S, Trinka E, Striano P, et al. Ukusebenza kwe-Cannabidiol nesimo se-clobazam: Ukubuyekezwa okuhlelekile nokuhlaziywa kwemeta. Isifo sokuwa. 2020; 61: 1090-1098. Buka okungaqondakali.
14. IHobbs JM, iVazquez AR, iRemijan ND, et al. Ukuhlolwa kwe-pharmacokinetics kanye namandla amakhulu okulwa nokuvuvukala kwamalungiselelo amabili we-oral cannabidiol kubantu abadala abaphilile. I-Phytother Res. 2020; 34: 1696-1703. Buka okungaqondakali.
15. U-Ebrahimi-Fakhari D, u-Agricola KD, uTudor C, uKrueger D, uFranz DN. I-Cannabidiol Iphakamisa Ukuqondiswa Kwemishini Yezinga Le-Rapamycin Inhibitor Ezigulini Ezine-Tuberous Sclerosis Complex. I-Pediatr Neurol. 2020; 105: 59-61. Buka okungaqondakali.
16. de Carvalho Reis R, Almeida KJ, da Silva Lopes L, de Melo Mendes CM, Bor-Seng-Shu E. Ukusebenza kanye nomlando omubi we-cannabidiol ne-cannabis yokwelapha yesifo sokuwa esingazweli ekwelashweni: Ukubuyekezwa okuhlelekile nokuhlaziywa kwe-meta. Isifo sokuwa Behav. 2020; 102: 106635. Buka okungaqondakali.
17. I-Darweesh RS, i-Khamis TN, i-El-Elimat T. Umphumela we-cannabidiol ku-pharmacokinetics ye-carbamazepine kumagundane. UNaunyn Schmiedebergs Arch Pharmacol. 2020. Buka okungaqondakali.
18. ICrockett J, Critchley D, Tayo B, Berwaerts J, Morrison G. Isigaba 1, ukuhlolwa okungahleliwe, kwe-pharmacokinetic komphumela wezingoma ezahlukahlukene zokudla, ubisi lonke, notshwala ekuvezweni kwe-cannabidiol nokuphepha ezifundweni ezinempilo. Isifo sokuwa. 2020; 61: 267-277. Buka okungaqondakali.
19. UChesney E, u-Oliver D, uGreen A, et al. Imiphumela emibi ye-cannabidiol: ukubuyekezwa okuhlelekile nokuhlaziywa kwemeta kokuhlolwa komtholampilo okungahleliwe. I-Neuropsychopharmacology. 2020. Buka okungaqondakali.
20. UBen-Menachem E, uGunning B, u-Arenas Cabrera CM, et al. Isivivinyo Esingahleliwe Sesigaba II Ukuhlola Okungenzeka Kokuhlangana Kwemithi Yezidakamizwa Nezidakamizwa ne-Stiripentol noma iValproate lapho kuhlanganiswe neCannabidiol ezigulini ezinesifo sokuwa. Izidakamizwa ze-CNS. 2020; 34: 661-672. Buka okungaqondakali.
21. UBass J, uLinz DR. Icala Lobuthi kusuka ku-Cannabidiol Gummy Ingestion. UCureus. 2020; 12: e7688. Buka okungaqondakali.
22. I-Hampson AJ, i-Grimaldi M, i-Axelrod J, i-Wink D. I-Cannabidiol kanye (-) ne-Delta9-tetrahydrocannabinol yi-antioxidants ye-neuroprotective. I-Proc Natl Acad Sci U S A. 1998; 95: 8268-73. Buka okungaqondakali.
23. IHacke ACM, uLima D, de Costa F, et al. Ukuhlola umsebenzi we-antioxidant we [delta] -tetrahydrocannabinol ne-cannabidiol kwizicashunwa zeCannabis sativa. Umhlaziyi. 2019; 144: 4952-4961. Buka okungaqondakali.
24. UMadden K, uTanco K, uBruera E. Ukusebenzisana Okubalulekile Kwezidakamizwa Nezidakamizwa Phakathi Kwemethadone neCannabidiol. Izifo zezingane. 2020; e20193256. Buka okungaqondakali.
25. IHazekamp A. Inkinga ngamafutha e-CBD. I-Med Cannabis Cannabinoids. 2018 Jun; 1: 65-72.
26. I-Xu DH, i-Cullen BD, i-Tang M, i-Fang Y. Ukusebenza kwe-Topical Cannabidiol Oil ku-Sympomatic Relief ye-Peripheral Neuropathy ye-Lower Extremities. ICurr Pharm Biotechnol. 2019 Dis 1. Buka okungaqondakali.
27. de Faria SM, de Morais Fabrício D, Tumas V, et al. Imiphumela yokuphathwa okunamandla kwe-cannabidiol ekukhathazekeni nasekuthuthumeleni okubangelwa yi-Simulated Public Speaking Test ezigulini ezinesifo sikaParkinson. J I-Psychopharmacol. 2020 uJan 7: 269881119895536. Buka okungaqondakali.
28. UNitecka-Buchta A, uNowak-Wachol A, uWachol K, et al. Umphumela we-Myorelaxant we-Transdermal Cannabidiol Application ezigulini ezine-TMD: Isivivinyo Esingahleliwe, Esiphofu kabili. UJ Clin Med. 2019 uNov 6; 8. pii: E1886. Buka okungaqondakali.
29. IMasataka N. Imiphumela ye-Anxiolytic Yokwelapha Okuphindaphindiwe Kwe-Cannabidiol Kwentsha Enenkinga Yokukhathazeka Komphakathi. Ingqondo yangaphambili. 2019 Novemba 8; 10: 2466. Buka okungaqondakali.
30. U-Appiah-Kusi E, Petros N, Wilson R, et al. Imiphumela yokwelashwa kwesikhashana kwe-cannabidiol ekuphenduleni ekucindezelekeni komphakathi ezifundweni ezisengozini enkulu yomtholampilo yokuthola isifo sengqondo. I-Psychopharmacology (i-Berl). 2020 Jan 8. Buka okungaqondakali.
31. UHussain SA, uDlugos DJ, uCilio MR, Parikh N, Oh A, Sankar R. Synthetic pharmaceutical grade cannabidiol ekwelapheni ama-spasms wezinsana aphikisayo: Isifundo se-multicenter phase-2. Isifo sokuwa Behav. 2020 uJan; 102: 106826. Buka okungaqondakali.
32. UKlotz KA, Grob D, Hirsch M, Metternich B, Schulze-Bonhage A, Jacobs J. Ukusebenza nokubekezelela kwe-Synthetic Cannabidiol for Treatment of Drug Resistant Epilepsy. Ngaphambili Neurol. 2019 Disemba 10; 10: 1313. Buka okungaqondakali.
33. "IGW Pharmaceuticals plc kanye ne-Its U.S. Subsidiary Greenwich Biosciences, Inc. Imemezela Ukuthi Isixazululo Somlomo Se-EPIDIOLEX® (cannabidiol) Sihlelelwe Isikhathi Futhi Akuseyona Into Elawulwayo." I-GW Pharmaceuticals, 6 Ephreli 2020. http://ir.gwpharm.com/node/11356/pdf. Isitatimende sephephandaba.
34. UWiemer-Kruel A, uStiller B, uBast T. Cannabidiol Uxhumana Ngokuphawulekayo ne-Everolimus-Umbiko Wesiguli EsineTuberous Sclerosis Complex. Neuropediatrics. 2019. Buka okungaqondakali.
35. Ukubuyekezwa Kwabathengi be-FDA: Okufanele Ukwazi Ngokusebenzisa Insangu, Kubandakanya i-CBD, Lapho Ukhulelwe noma Uncelisa. U. S. Food and Drug Administration (FDA). Okthoba 2019. Kutholakala ku: https://www.fda.gov/consumers/consumer-updates/what-you-should-now-about-using-cannabis-including-cbd-when-pregnant-or-breastfeeding.
36. UTaylor L, Crockett J, Tayo B, Morrison G. A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment. UJ Clin Pharmacol. 2019; 59: 1110-1119. Buka okungaqondakali.
37. USzaflarski JP, uHernando K, uBebin EM, et al. Izinga eliphakeme le-plasma le-cannabidiol lihlotshaniswa nempendulo yokubanjwa ngcono kokulandela ukwelashwa ngebanga lemithi i-cannabidiol. Isifo sokuwa Behav. 2019; 95: 131-136. Buka okungaqondakali.
38. UPretzsch CM, uVoinescu B, uMendez MA, et al. Umphumela we-cannabidiol (i-CBD) ekusebenzeni kwemvamisa ephansi nasekuxhumaneni okusebenzayo ebuchosheni babantu abadala abane-Autism spectrum disorder (ASD) nangaphandle kwayo. J I-Psychopharmacol. 2019: 269881119858306. Buka okungaqondakali.
39. UPretzsch CM, uFreyberg J, uVoinescu B, et al. Imiphumela ye-cannabidiol ekujabuliseni ubuchopho nezinhlelo zokuvimbela; isilingo sedosi esisodwa esilawulwa ngokungahleliwe ngesikhathi sokubukwa kwesibonisi samagnetic kubantu abadala abane-disorder ye-autism nangaphandle kwayo. I-Neuropsychopharmacology. 2019; 44: 1398-1405. Buka okungaqondakali.
40. UPatrician A, uVeric-Bratincevic M, uMijacika T, et al. Ukuhlolwa kwendlela entsha yokulethwa kwe-Oral Cannabidiol ezifundweni ezinempilo: Isifundo se-Pharmacokinetics Study esenziwe ngokungahleliwe, esimpumputhe kabili. U-Adv Ther. 2019. Buka okungaqondakali.
41. UMartin RC, uGaston TE, uThompson M, et al. Ukusebenza kwengqondo kulandela ukusetshenziswa kwesikhathi eside kwe-cannabidiol kubantu abadala abanesithuthwane esingazweli ekwelashweni. Isifo sokuwa Behav. 2019; 97: 105-110. Buka okungaqondakali.
42. Leino AD, Emoto C, Fukuda T, Privitera M, Vinks AA, Alloway RR. Ubufakazi bokusebenzisana okuphawulekayo kwezidakamizwa phakathi kwezidakamizwa ne-tacrolimus. NginguJ J ukufakelwa kabusha. 2019; 19: 2944-2948. Buka okungaqondakali.
43. I-Laux LC, i-Bebin EM, i-Checketts D, et al. Ukuphepha kwesikhathi eside nokusebenza kwe-cannabidiol ezinganeni nakubantu abadala abane-Lennox-Gastaut syndrome noma i-Dravet syndrome emelana nokwelashwa: Imiphumela yohlelo lokufinyelela olwandisiwe. Isithuthwane Res. 2019; 154: 13-20. Buka okungaqondakali.
44. UKnaub K, Sartorius T, Dharsono T, Wacker R, Wilhelm M, Schön C. A Novel Self-Emulsifying Drug Delivery System (SEDDS) Ngokuya nge-VESIsorb Formulation Technology Ukuthuthukisa ukutholakala komlomo kweCannabidiol ezifundweni ezinempilo. Ama-molecule. 2019; 24. i-pii: E2967. Buka okungaqondakali.
45. UKlotz KA, Hirsch M, Heers M, Schulze-Bonhage A, Jacobs J. Imiphumela ye-cannabidiol kumazinga we-brivaracetam plasma. Isifo sokuwa. 2019; 60: e74-e77. Buka okungaqondakali.
46. UHeussler H, uCohen J, uSilove N, et al. Isigaba i-1/2, ukuhlolwa kwelebula evulekile kokuphepha, ukubekezelela, nokusebenza kwe-transdermal cannabidiol (ZYN002) ekwelapheni isifo esibuthakathaka se-X syndrome. J Neurodev Ukungezwani. 2019; 11: 16. Buka okungaqondakali.
47. Umbhede DG, Cook H, Ortori C, Barrett D, Lund JN, O'Sullivan SE. I-Palmitoylethanolamide ne-Cannabidiol Vimbela i-Hyperpermeability ebangelwa ukuvuvukala kwe-Human Gut In Vitro ne-In Vivo-A Randomised, Placebo-controlled, Double-blind Trial Trial. I-Inflamm Bowel Dis. 2019; 25: 1006-1018. Buka okungaqondakali.
48. UBirnbaum AK, uKaranam A, uMarino SE, et al. Umphumela wokudla kuma-pharmacokinetics we-cannabidiol amaphilisi omlomo ezigulini zabantu abadala abanesithuthwane esiphikisayo. Isifo sokuwa. 2019 Aug; 60: 1586-1592. Buka okungaqondakali.
49. U-Arkell TR, uLintzeris N, uKevin RC, et al. Okuqukethwe kwe-Cannabidiol (CBD) ku-cannabis ephefumulelwe akuvimbeli ukukhubazeka kwe-tetrahydrocannabinol (THC) okuthinta ukushayela nokuqonda. I-Psychopharmacology (i-Berl). 2019; 236: 2713-2724. Buka okungaqondakali.
50. U-Anderson LL, u-Absalom NL, u-Abelev SV, et al. I-cannabidiol ephethwe yi-Coadministered kanye ne-clobazam: Ubufakazi bokutholwa kokusebenzisana kwe-pharmacodynamic kanye ne-pharmacokinetic. Isifo sokuwa. 2019. Buka okungaqondakali.
51. Imininingwane yomkhiqizo weMarinol. AbbVie. ENyakatho Chicago, IL 60064. Agasti 2017.Kutholakala ku: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf.
52. I-Epidiolex (cannabidiol) enquma imininingwane. IGreenwich Biosciences, Inc., iCarlsbad, CA, 2019. Itholakala ku: https://www.epidiolex.com/sites/default/files/EPIDIOLEX_Full_Prescribing_Information.pdf (kufinyelelwe ngomhla ka-5/9/2019)
53. Isitatimende esivela kuKhomishani we-FDA uScot Gottlieb, MD, ngokusayinwa koMthetho Wokuthuthukiswa Kwezolimo kanye nokulawulwa kwe-ejensi yemikhiqizo equkethe i-cannabis kanye nezakhi ezitholakala nge-cannabis. Iwebhusayithi ye-U.S.U. Kutholakala ku: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-signing-agriculture-improvement-act-and-agencys. (Kufinyelelwe ngoMeyi 7, 2019).
54. Umthetho Wezokuthuthukiswa Kwezolimo, S. 10113, 115th Cong. noma S. 12619, 115th Cong. .
55. Ukuphathwa Kwezokuphathwa Kwezidakamizwa, uMnyango Wezobulungiswa. Amashejuli Ezinto Ezilawulwayo: Ukubekwa Kusheduli V Yezidakamizwa Ezithile Ezamukelwe yi-FDA Eziqukethe I-Cannabidiol; Ushintsho Oluhambelana Nezimfuneko Zemvume. I-oda lokugcina. Ukubhaliswa Kwezezimali. 2018 Sep 28; 83: 48950-3. Buka okungaqondakali.
56. ISchoedel KA, Szeto I, Setnik B, et al. Ukuhlolwa okungahle kube khona kokuhlukunyezwa kwe-cannabidiol (i-CBD) kubasebenzisi bokuzithokozisa be-polydrug: Isivivinyo esilawulwa ngokungahleliwe, esiyimpumputhe, nesilawulwa. Isifo sokuwa Behav. 2018 Nov; 88: 162-171. i-doi: 10.1016 / j.yebeh.2018.07.027. I-Epub 2018 Oct 2. Buka okungaqondakali.
57. UDevinsky O, Verducci C, Thiele EA, et al. Ukusetshenziswa kwelebula evulekile kwe-CBD ehlanzwe kakhulu (i-Epidiolex®) ezigulini ezinesifo sokushoda kwe-CDKL5 kanye ne-Aicardi, Dup15q, neDoose syndromes. Isifo sokuwa Behav. 2018 Septhemba; 86: 131-137. I-Epub 2018 Jul 11. Buka okungaqondakali.
58. USzaflarski JP, uBebin EM, umsiki G, uDeWolfe J, et al. I-Cannabidiol ithuthukisa imvamisa nobukhali bokuquleka futhi inciphisa izehlakalo ezimbi kusifundo esizoba khona selebuli evulekile. Isifo sokuwa Behav. 2018 Okthoba; 87: 131-136. I-Epub 2018 Aug 9. Buka okungaqondakali.
59. ILinares IM, iZuardi AW, iPereira LC, et al. I-Cannabidiol iveza ijika lempendulo ye-U elime ngendlela evunyiwe ekuhlolweni kokukhuluma komphakathi. UBraz J Psychiatry. 2019 UJan-Feb; 41: 9-14. I-Epub 2018 Oct 11. Buka okungaqondakali.
60. I-Poklis JL, Mulder HA, Ukuthula MR. Ukukhonjwa okungalindelekile kwe-cannabimimetic, 5F-ADB, ne-dextromethorphan kuma-cannabidiol e-liquids athengiswayo. I-Forensic Sci Int. 2019 uJan; 294: e25-e27. I-Epub 2018 Nov 1. Buka okungaqondakali.
61. Kulimaze i-YL, i-Spriggs S, i-Alishayev J, et al. I-Cannabidiol Yokwehliswa Kwesifiso Esenziwe Nge-Cue-Ukukhathazeka Nabantu Abangavumeli Izidakamizwa Abantu Abane-Disorder Use Disorder: Isivivinyo Esilawulwa Nge-Placebo Esilawulwa Kabili. NginguJ J Psychiatry. 2019: uhlelo lokusebenza201918101191. Buka okungaqondakali.
62. UThiele EA, Marsh ED, French JA, et al. I-Cannabidiol ezigulini ezinokuquleka okuhambisana ne-Lennox-Gastaut syndrome (GWPCARE4): isilingo esilawulwa nge-placebo esilawulwa ngokungahleliwe, esimpumputhe kabili. I-Lancet. 2018 uMar 17; 391: 1085-1096. Buka okungaqondakali.
63. UDevinsky O, uPatel AD, uCross JH, et al. Umphumela weCannabidiol Ekuqubuzeni Kokwehla kuLennox-Gastaut Syndrome. N Engl J Med. 2018 Meyi 17; 378: 1888-1897. Buka okungaqondakali.
64. UPavlovic R, uNenna G, uCalvi L, et al. Izici Zekhwalithi ze "Amafutha e-Cannabidiol": Okuqukethwe kwe-Cannabinoids, i-Terpene Fingerprint kanye ne-Oxidation Stability of European Commercially Preparations. Ama-molecule. 2018 uMeyi 20; 23. pii: E1230. Buka okungaqondakali.
65. UJannasch F, uKröger J, uSchulze MB. Amaphethini Okudla kanye nohlobo 2 Lwesifo Sikashukela: Ukubuyekezwa Kwezincwadi Ezihlelekile kanye Nokuhlaziywa Kwemeta Yezifundo Ezizokwenzeka. J Umsoco. 2017 Juni; 147: 1174-1182. Buka okungaqondakali.
66. UNaftali T, Mechulam R, Marii A, et al. Umthamo ophansi we-cannabidiol uphephile kepha awusebenzi ekwelapheni iSifo sikaCrohn, isilingo esilawulwa ngokungahleliwe. I-Dig Dis Sci. 2017 uJuni; 62: 1615-20. Buka okungaqondakali.
67. IKaplan EH, i-Offermann EA, iSievers JW, iComi AM. Ukwelashwa kwe-Cannabidiol ngokuhlaselwa okukhanyelayo ku-Sturge-Weber Syndrome. I-Pediatr Neurol. 2017 Juni; 71: 18-23.e2. Buka okungaqondakali.
68. U-Yeshurun ​​M, uShippilberg O, uHerscovici C, et al. I-Cannabidiol yokuvimbela isifo se-graft-versus-host-disease ngemuva kokufakelwa kabusha kwe-allogeneic hematopoietic cell: imiphumela yocwaningo lwesigaba II. Ukufakelwa kabusha kwe-Biol Blood Marrow. 2015 Okthoba; 21: 1770-5. Buka okungaqondakali.
69. UGeffrey AL, uPollack SF, uBruno PL, uThiele EA. Ukusebenzisana kwezidakamizwa nezidakamizwa phakathi kwe-clobazam ne-cannabidiol ezinganeni ezinesithuthwane esiphikisayo. Isifo sokuwa. 2015 Aug; 56: 1246-51. Buka okungaqondakali.
70. UDevinsky O, uMarsh E, uFriedman D, et la. I-Cannabidiol ezigulini ezinesithuthwane esingazweli ekwelashweni: isivivinyo sokungenelela esinelebula evulekile. ILancet Neurol. 2016 Mar; 15: 270-8. Buka okungaqondakali.
71. I-97021 Jadoon KA, iRatcliffe SH, iBarrett DA, et al. Ukusebenza nokuphepha kwe-cannabidiol ne-tetrahydrocannabivarin kumapharamitha we-glycemic ne-lipid ezigulini ezinesifo sikashukela sohlobo lwe-2: isifundo esilawulwa ngokungahleliwe, esimpumputhe, esilawulwa yi-placebo, esifanayo. Ukunakekelwa yisifo sikashukela. 2016 Okthoba; 39: 1777-86. Buka okungaqondakali.
72. UGofshteyn JS, uWilfong A, uDevinsky O, et al. I-Cannabidiol njengokwelashwa okungaba khona kwesifo sokuwa esihlobene nokutheleleka okutheleleka (i-FIRES) ezigabeni ezinzima nezihlala njalo. J Ingane Neurol. 2017 uJan; 32: 35-40. Buka okungaqondakali.
73. UHess EJ, Moody KA, Geffrey AL, et al. I-Cannabidiol njengokwelashwa okusha kwesifo sokuwa okungazweli emthini ku-tuberous sclerosis complex. Isifo sokuwa. 2016 Okthoba; 57: 1617-24.
74. UGaston TE, uBebin EM, umsiki GR, uLiu Y, uSzaflarski JP; Uhlelo lwe-UAB CBD. Ukusebenzisana phakathi kwe-cannabidiol nezidakamizwa ezisetshenziswa kakhulu zokulwa nesifo sokuwa. Isifo sokuwa. 2017 Septhemba; 58: 1586-92. Buka okungaqondakali.
75. UDevinsky O, uCross JH, uLaux L, et al. Ukuhlolwa kwe-cannabidiol ngokuhlaselwa okungazweli emthini ku-Dravet Syndrome. N Engl J Med. 2017 uMeyi 25; 376: 2011-2020. Buka okungaqondakali.
76. UBonn-Miller MO, uLoflin MJE, uThomas BF, uMarcu JP, uHyke T, uVandrey R. Ukubhala ngokunemba kokukhishwa kwe-cannabidiol okuthengiswa online. I-JAMA 2017 Nov; 318: 1708-9. Buka okungaqondakali.
77. UMalfait AM, uGallily R, uSumariwalla PF, et al. I-non-psychoactive cannabis-constituent cannabidiol iyi-oral anti-arthritic therapeutic ku-murine collagen eyenziwe i-arthritis. I-Proc Natl Acad Sci USA 2000; 97: 9561-6. Buka okungaqondakali.
78. IFormukong EA, u-Evans AT, u-Evans FJ. Umsebenzi we-analgesic nowokulwa nokuvuvukala wezakhi zeCannabis sativa L. Ukuvuvukala 1988; 12: 361-71. Buka okungaqondakali.
79. UValvassori SS, u-Elias G, de Souza B, et al. Imiphumela ye-cannabidiol ekukhiqizeni ukucindezeleka okwenziwe nge-amphetamine kwimodeli yezilwane ye-mania. UJ Psychopharmacol 2011; 25: 274-80. Buka okungaqondakali.
80. U-Esposito G, uScuderi C, uSavani C, et al. I-Cannabidiol ku-vivo ifiphaza i-beta-amyloid eyenziwe nge-neuroinfigueation ngokucindezela i-IL-1beta ne-iNOS expression. UBr J Pharmacol 2007; 151: 1272-9. Buka okungaqondakali.
81. U-Esposito G, uDe Filippis D, uMaiuri MC, et al. ICannabidiol inhibit inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons ngokusebenzisa i-p38 MAP kinase nokubandakanyeka kwe-NF-kappaB. INeurosci Lett 2006; 399 (1-2): 91-5. Buka okungaqondakali.
82. U-Iuvone T, u-Esposito G, uDe Filippis D, et al. I-Cannabidiol: umuthi omusha othembisayo wezifo ze-neurodegenerative? I-CNS Neurosci Ther 2009; 15: 65-75. Buka okungaqondakali.
83. I-Bisogno T, i-Di Marzo Y. Indima yohlelo lwe-endocannabinoid ku-Alzheimer's's disease: amaqiniso nokucabanga. ICurr Pharm Des 2008; 14: 2299-3305. Buka okungaqondakali.
84. I-Zuardi AW. I-Cannabidiol: kusuka ku-cannabinoid engasebenzi kuya kumuthi onezenzo eziningi. UMfu Bras Psiquiatr 2008; 30: 271-80. Buka okungaqondakali.
85. Izzo AA, Borelli F, Capasso R, et al. Izitshalo ezingama-non-psychotropic plant cannabinoids: amathuba amasha okwelapha avela emthini wasendulo. Amathrendi Pharmacol Sci 2009; 30: 515-27. Buka okungaqondakali.
86. I-Booz GW. I-Cannabidiol njengecebo elivelayo lokwelapha lokunciphisa umthelela wokuvuvukala ekucindezelekeni kwe-oxidative. I-Radic Biol Med yamahhala ngo-2011; 51: 1054-61. Buka okungaqondakali.
87. U-Pickens JT. Umsebenzi wokulalisa insangu maqondana nokuqukethwe kwawo kwe-delta’-trans-tetrahydrocannabinol kanye ne-cannabidiol. UBr J Pharmacol 1981; 72: 649-56. Buka okungaqondakali.
88. Monti JM. Imiphumela efana ne-Hypnotic ye-cannabidiol kumagundane. I-Psychopharmacology (Berl) 1977; 55: 263-5. Buka okungaqondakali.
89. UKarller R, iTurkanis SA. Subacute ukwelashwa kwe-cannabinoid: umsebenzi we-anticonvulsant kanye nokuhoxiswa kokuthakazelisa kumagundane. UBr J Pharmacol 1980; 68: 479-84. Buka okungaqondakali.
90. UKarller R, uCely W, iTurkanis SA. Umsebenzi we-anticonvulsant we-cannabidiol ne-cannabinol. Impilo Sci 1973; 13: 1527-31. Buka okungaqondakali.
91. I-Consroe PF, i-Wokin AL. Ukusebenzisana kwe-Anticonvulsant kwe-cannabidiol ne-ethosuximide kumagundane. UJ Pharm Pharmacol 1977; 29: 500-1. Buka okungaqondakali.
92. I-Consroe P, i-Wolkin A. Ukuqhathaniswa kwezidakamizwa ze-Cannabidiol-antiepilpetic kanye nokusebenzisana ekubanjweni kokuhlolwa okwenziwe ngamagundane. UJ Pharmacol Exp Ther 1977; 201: 26-32. Buka okungaqondakali.
93. UCarlini EA, uLeite JR, uTannhauser M, uBerardi AC. Incwadi: I-Cannabidiol ne-Cannabis sativa kukhishwa ukuvikela amagundane namagundane kuma-convulsive agents. UJ Pharm Pharmacol 1973; 25: 664-5. Buka okungaqondakali.
94. UCryan JF, uMarkou A, uLucki I. Ukuhlola umsebenzi we-antidepressant kumagundane: intuthuko yakamuva nezidingo zesikhathi esizayo. Amathrendi Pharmacol Sci 2002; 23: 238-45. Buka okungaqondakali.
95. U-El-Alfy AT, u-Ivey K, uRobinson K, et al. Umphumela ofana ne-antidepressant we-delta9-tetrahydrocannabinol namanye ama-cannabinoids ahlukaniswe ne-Cannabis sativa L. Pharmacol Biochem Behav 2010; 95: 434-42. Buka okungaqondakali.
96. I-Resstel LB, iTavares RF, iLisboa SF, et al. Ama-5-HT1A receptors abandakanyekile ekunciphiseni okwenziwe yi-cannabidiol kwezimpendulo zokuziphatha nezenhliziyo ekucindezelekeni okukhulu kumagundane. UBr J Pharmacol 2009; 156: 181-8. Buka okungaqondakali.
97. IGranjeiro EM, iGomes FV, ​​iGuimaraes FS, et al. Imiphumela yokuphathwa kwangaphakathi kwe-cannabidiol ekuphenduleni kwenhliziyo nokuziphatha ekucindezelekeni okukhulu kokuzibamba. I-Pharmacol Biochem Behav 2011; 99: 743-8. Buka okungaqondakali.
98. UMurillo-Rodriguez E, uMillan-Aldaco D, uPalomero-Rivero M, et al. I-Cannabidiol, indawo yeCannabis sativa, ihlehlisa ukulala kumagundane. FEBS Lett 2006; 580: 4337-45. Buka okungaqondakali.
99. UDe Filippis D, u-Esposito G, uCirillo C, et al. I-Cannabidiol inciphisa ukuvuvukala kwamathumbu ngokulawulwa kwe-axis ye-neuroimmune. Ama-PLoS One 2011; 6: e28159. Buka okungaqondakali.
100. UBhattacharyya S, uFusar-Poli P, uBorgwardt S, et al. Ukushintshashintsha komsebenzi we-mediotemporal kanye ne-ventrostriatal kubantu yi-Delta9-tetrahydrocannabinol: isisekelo se-neural semiphumela yeCannabis sativa ekufundeni nasengqondweni. I-Arch Gen Psychiatry 2009; 66: 442-51. Buka okungaqondakali.
101. UDalton WS, uMartz R, uLemberger L, et al. Ithonya le-cannabidiol emiphumeleni ye-delta-9-tetrahydrocannabinol. I-Clin Pharmacol Ther 1976; 19: 300-9. Buka okungaqondakali.
102. IGuimaraes VM, iZuardi AW, iDel Bel EA, iGuimaraes FS. I-Cannabidiol ikhulisa ukubonakaliswa kwe-Fos kuma-nucleus accumbens kepha hhayi ku-dorsal striatum. ILife Sci 2004; 75: 633-8. Buka okungaqondakali.
103. IMoreira FA, iGuimaraes FS. I-Cannabidiol ivimbela i-hyperlocomotion ebangelwa izidakamizwa ze-psychomimetic kumagundane. I-Eur J Pharmacol 2005; 512 (2-3): 199-205. Buka okungaqondakali.
104. Isikhathi eside LE, Chesworth R, Huang XF, et al. Ukuqhathanisa kokuziphatha kwe-Delta9-tetrahydrocannabinol enamandla futhi engapheli ne-cannabidiol ku-C57BL / 6JArc amagundane. I-Int J Neuropsychopharmacol 2010; 13: 861-76. Buka okungaqondakali.
105. UZuardi AW, uRodriguez JA, uCunha JM. Imiphumela ye-cannabidiol kumamodeli wezilwane ukuqagela komsebenzi we-antipsychotic. I-Psychopharmacology (Berl) 1991; 104: 260-4. Buka okungaqondakali.
106. IMalone DT, uJongejan D, Taylor DA. I-Cannabidiol iguqula ukuncipha kokuxhumana komphakathi okukhiqizwa yi-low low Delta-tetrahydrocannabinol kumagundane. I-Pharmacol Biochem Behav 2009; 93: 91-6. Buka okungaqondakali.
107. ISchubart CD, uSommer IE, uFusar-Poli P, et al. I-Cannabidiol njengokwelashwa okungenzeka kube yi-psychosis. I-Eur Neuropsychopharmacol 2014; 24: 51-64. Buka okungaqondakali.
108. ICampos AC, iMoreira FA, iGomes FV, ​​et al. Izindlela eziningi ezihilelekile ekutholakaleni kwe-spectrum enkulu ye-cannabidiol ezinkingeni zengqondo. IPhilos Trans R Soc Lond B Biol Sci 2012; 367: 3364-78. Buka okungaqondakali.
109. UFusar-Poli P, u-Allen P, uBhattacharyya S, et al. Ukushintshashintsha kokuxhuma okusebenzayo ngenkathi kucutshungulwa ngokomzwelo yiDelta 9-tetrahydrocannabinol ne-cannabidiol. I-Int J Neuropsychopharmacol 2010; 13: 421-32. Buka okungaqondakali.
110. ICasarotto PC, Gomes FV, ​​Resstel LB, Guimaraes FS. Umphumela we-Cannabidiol inhibitory ekuziphatheni kokungcwaba imabula: ukubandakanyeka kwama-receptors e-CB1. I-Behav Pharmacol 2010; 21: 353-8. Buka okungaqondakali.
111. U-Uribe-Marino A, uFrancisco A, uCastiblanco-Urbina MA, et al. Imiphumela yokulwa ne-anti-aversive ye-cannabidiol ekuziphatheni okwenziwe ngaphakathi kokwesaba okukhishwe yimodeli yokuziphatha kokuhlaselwa ngokwesaba okususelwa kudlame vs inyoka yasendle i-Epicrate cenchria crassus yokulwa neparadigm. I-Neuropsychopharmacology 2012; 37: 412-21. Buka okungaqondakali.
112. ICampos AC, iGuimaraes FS. Ukwenza kusebenze ama-5HT1A receptors axhumanisa imiphumela ye-anxiolytic ye-cannabidiol kumodeli ye-PTSD. I-Behav Pharmacol 2009; 20: S54.
113. I-Resstel LB, i-Joca SR, i-Moreira FA, et al. Imiphumela ye-cannabidiol ne-diazepam kuzimpendulo zokuziphatha nezenhliziyo ezibangelwa ukwesaba okunemibandela yesimo kumagundane. I-Behav Brain Res 2006; 172: 294-8. Buka okungaqondakali.
114. UMoreira FA, i-Aguiar DC, iGuimaraes FS. Umphumela ofana ne-anxiolytic we-cannabidiol ekuhlolweni kwempikiswano ye-Vogel. IProg Neuropsychopharmacol Biol Psychiatry 2006; 30: 1466-71. Buka okungaqondakali.
115. U-Onaivi ES, Green MR, Martin BR. Ukuchazwa kwamakhemikhali kwama-cannabinoids ku-maze ephakeme ephakeme. UJ Pharmacol Exp Ther 1990; 253: 1002-9. Buka okungaqondakali.
116. IGuimaraes FS, uChairetti TM, iGraeff FG, iZuardi AW. Umphumela wokukhathazeka we-cannabidiol ku-plus-maze ephakeme. I-Psychopharmacology (Berl) 1990; 100: 558-9. Buka okungaqondakali.
117. UMagen I, u-Avraham Y, u-Ackerman Z, et al. I-Cannabidiol ithuthukisa ukukhubazeka kwengqondo nokuqonda kwezimoto kumagundane ane-bile duct ligation. UJ Hepatol 2009; 51: 528-34. Buka okungaqondakali.
118. URajesh M, uMukhopadhyay P, uBatkai S, et al. I-Cannabidiol inciphisa ukukhubazeka kwenhliziyo, ukucindezeleka okwenziwe nge-oxidative, i-fibrosis, nokuvuvukala kanye nokufa kweseli okukhombisa izindlela ku-cardiomyopathy yesifo sikashukela. UJ Am Coll Cardiol 2010; 56: 2115-25. Buka okungaqondakali.
119. U-El-Remessy AB, uKhalifa Y, u-Ola S, et al. I-Cannabidiol ivikela ama-neuron we-retina ngokulondoloza umsebenzi we-glutamine synthetase kwisifo sikashukela. I-Mol Vis 2010; 16: 1487-95. Buka okungaqondakali.
120. U-El-Remessy AB, u-Al-Shabrawey M, uKhalifa Y, et al. I-Neuroprotective kanye ne-retina barriers-ekulondolozeni imiphumela ye-cannabidiol kusifo sikashukela sokuhlola. NginguJ J Pathol 2006; 168: 235-44. Buka okungaqondakali.
121. URajesh M, uMukhopadhyay P, uBatkai S, et al. I-Cannabidiol inciphisa i-glucose ephezulu-ikhuthaza ukuphendula kokuvuvukala kwamaseli endothelial nokuphazamiseka kwesithiyo. NginguJ J Physiol Heart Circ Physiol 2007; 293: H610-H619. Buka okungaqondakali.
122. IToth CC, uJedrzejewski NM, u-Ellis CL, uFrey WH. Ukushintshashintsha kwe-Cannabinoid-mediated of neuropathic pain and microglial accumulation on a model of murine type 1 diabetic peripheral neuropathic pain. I-Mol Pain 2010; 6: 16. Buka okungaqondakali.
123. U-Aviello G, uRomano B, uBorrelli F, et al. Imiphumela ye-Chemopreventive ye-non-psychotropic phytocannabinoid cannabidiol kumdlavuza we-colon wokuhlola. UJ Mol Med (Berl) 2012; 90: 925-34. Buka okungaqondakali.
124. ULee CY, Wey SP, uLiao MH, et al. Ucwaningo lokuqhathanisa nge-apoptosis eyenziwe nge-cannabidiol kuma-murine thymocytes namaseli we-EL-4 thymoma. I-Int Immunopharmacol 2008; 8: 732-40. Buka okungaqondakali.
125. UMassi P, uValenti M, uVaccani A, et al. I-5-Lipoxygenase ne-anandamide hydrolase (FAAH) ixhumanisa umsebenzi we-antitumor we-cannabidiol, i-cannabinoid engeyona eyengqondo. UJ Neurochem 2008; 104: 1091-100. Buka okungaqondakali.
126. UValenti M, Massi P, Bolognini D, et al. I-Cannabidiol, i-non-psychoactive cannabinoid compound ivimbela ukufuduka kwamaseli we-glioma kanye nokuhlasela. I-34th National Congress ye-Italy Society of Pharmacology 2009.
127. UTorres S, uLorente M, uRodriguez-Fornes F, et al. Ukwelashwa okuhlanganisiwe kwangaphambi kokuchazwa kwama-cannabinoids ne-temozolomide ngokumelene ne-glioma. I-Mol Cancer Ther 2011; 10: 90-103. Buka okungaqondakali.
128. UJacobsson SO, uRongard E, uStridh M, et al. Imiphumela encike kuSerum ye-tamoxifen kanye ne-cannabinoids ekusebenzeni kweseli le-C6 glioma. I-Biochem Pharmacol 2000; 60: 1807-13. Buka okungaqondakali.
129. UShrivastava A, u-PM Kuzontkoski, uGroopman JE, uPrasad A. Cannabidiol ukhuthaza ukufa kwamaseli okuhleliwe kumaseli womdlavuza webele ngokuxhumanisa inkulumo ephambene phakathi kwe-apoptosis ne-autophagy. I-Mol Cancer Ther 2011; 10: 1161-72. Buka okungaqondakali.
130. UMcAllister SD, uMurase R, uChristian RT, et al. Izindlela ezilamula imiphumela ye-cannabidiol ekwehliseni ukwanda kwesifo somdlavuza webele, ukuhlasela, kanye ne-metastasis. Ukwelashwa Kwe-Cancer Res 2011; 129: 37-47. Buka okungaqondakali.
131. UMcAllister SD, uChristian RT, iPhalamende laseHorowitz, et al. I-Cannabidiol njenge-inhibitor yenoveli ye-Id-1 expression expression kumaseli womdlavuza webele onolaka. I-Mol Cancer Ther 2007; 6: 2921-7. Buka okungaqondakali.
132. ULigresti A, uMoriello AS, uStarowicz K, et al. Umsebenzi we-Antitumor wezitshalo ezingama-cannabinoids ngokugcizelela umphumela we-cannabidiol ku-carcinoma yebele lomuntu. UJ Pharmacol Exp Ther 2006; 318: 1375-87. Buka okungaqondakali.
133. UMassi P, uSolinas M, uCinquina V, uParolaro D.Cannabidiol njengomuthi onamandla wokulwa nomdlavuza. UBr J Clin Pharmacol 2013; 75: 303-12. Buka okungaqondakali.
134. I-Schubart CD, iSommer IE, van Gastel WA, et al. I-cannabis enokuqukethwe okuphezulu kwe-cannabidiol ihlotshaniswa nokuhlangenwe nakho okumbalwa kwengqondo. ISchizophr Res 2011; 130 (1-3): 216-21. Buka okungaqondakali.
135. U-Englund A, uMorrison PD, uNottage J, et al. I-Cannabidiol ivimbela i-THC-ephakanyiswe izimpawu ze-paranoid nokukhubazeka kwememori ethembeke ku-hippocampal. J I-Psychopharmacol 2013; 27: 19-27. Buka okungaqondakali.
136. UDevinsky O, uCilio MR, uCross H, et al. I-Cannabidiol: i-pharmacology kanye nendima engaba khona ekwelashweni kwesifo sokuwa nezinye izifo ze-neuropsychiatric. Isifo sokuwa 2014; 55: 791-802. Buka okungaqondakali.
137. I-Serpell MG, i-Notcutt W, i-Collin C. Ukusetshenziswa kwesikhathi eside kwe-Sativex: isivivinyo esinelebuli evulekile ezigulini ezine-spasticity ngenxa ye-multiple sclerosis. UJ Neurol 2013; 260: 285-95. Buka okungaqondakali.
138. UNotcutt W, uLangford R, uDavies P, et al. Iqembu elilawulwa yi-placebo, elihambisanayo, ukufundwa kokuhoxiswa okungahleliwe kwezihloko ezinezimpawu zokuqina ngenxa ye-multiple sclerosis ethola iSativex yesikhathi eside (nabiximols). IMult Scler 2012; 18: 219-28. Buka okungaqondakali.
139. UBrady CM, uDasGupta R, uDalton C, et al. Ucwaningo oluvulekile lwelebula lokukhishwa okususelwa ku-cannabis lokungasebenzi kahle kwesinye ku-advanced multiple sclerosis. IMult Scler 2004; 10: 425-33. Buka okungaqondakali.
140. UKavia RB, uDe Ridder D, uConstantinescu CS, et al. Isivivinyo esilawulwa ngokungahleliwe seSativex ukwelapha ukusebenza ngokweqile kwesifo sokuqina kwemithambo IMult Scler 2010; 16: 1349-59. Buka okungaqondakali.
141. UWade DT, PM Makela PM, House H, et al. Ukusetshenziswa kwesikhathi eside kokwelashwa okususelwa ku-cannabis ekuphambaneni nezinye izimpawu ku-multiple sclerosis. IMult Scler 2006; 12: 639-45. Buka okungaqondakali.
142. UNovotna A, Mares J, uRatcliffe S, et al. I-randomized, blind-blind-controlled, placebo-controlled group, parallel-group, ukucebisa-design design ye-nabiximols * (Sativex), njenge-add-on therapy, ezifundweni ezine-reflexory spasticity ezibangelwa yi-multiple sclerosis. I-Eur J Neurol 2011; 18: 1122-31. Buka okungaqondakali.
143. Sibutsetelo. Iwebhusayithi ye-GW Pharmaceuticals.Itholakala ku: http://www.gwpharm.com/about-us-overview.aspx. Kufinyelelwe: Meyi 31, 2015.
144. I-Cannabidiol Manje Ikhombisa Izithasiselo Zokudla. Iwebhusayithi Yemithi Yemvelo. https://naturalmedicines.therapeuticresearch.com/news/news-items/2015/march/cannabidiol-now-showing-up-in-dietary-supplements.aspx. (Kufinyelelwe ngoMeyi 31, 2015).
145. UZuardi AW, uCosme RA, uGraeff FG, uGuimaraes FS. Imiphumela ye-ipsapirone ne-cannabidiol ekukhathazekeni kokuhlola komuntu. J I-Psychopharmacol 1993; I-7 (1 Suppl): 82-8. Buka okungaqondakali.
146. Eighty EG, Fentiman AF Jr, Foltz RL. Ama-metabolites agcinwe isikhathi eside we-delta9- ne-delta8-tetrahydrocannabinols akhonjwe njengama-conjugates enoveli anamafutha. I-Res Commun Chem Pathol Pharmacol 1976; 14: 13-28. Buka okungaqondakali.
147. USamara E, uBialer M, uMechoulam R. Pharmacokinetics we-cannabidiol ezinjeni. Izidakamizwa ze-Metab Dispos 1988; 16: 469-72. Buka okungaqondakali.
148. I-Consroe P, iSandyk R, iSnider SR. Vula ukuhlolwa kwelebuli ye-cannabidiol ezinkingeni zokunyakaza ze-dystonic. I-Int J Neurosci 1986; 30: 277-82. Buka okungaqondakali.
149. UCrippa JA, uDerenusson GN, uFerrari TB, et al. Isisekelo se-Neural semiphumela ye-anxiolytic ye-cannabidiol (i-CBD) ekuphazamisweni kokukhathazeka komphakathi okujwayelekile: umbiko wokuqala. UJ Psychopharmacol 2011; 25: 121-30. Buka okungaqondakali.
150. I-Bornheim LM, i-Everhart ET, uLi J, uCorreia MA. Ukuchazwa kokungasebenzi kwe-cytochrome P450 ye-cannabidiol. I-Biochem Pharmacol 1993; 45: 1323-31. Buka okungaqondakali.
151. UHarvey DJ. Ukuncela, ukusabalalisa, kanye ne-biotransformation yama-cannabinoids. Insangu Nomuthi. 1999; 91-103.
152. UYamaori S, Ebisawa J, Okushima Y, et al. Ukuvinjelwa okunamandla kwe-cytochrome yomuntu i-P450 3A isoforms yi-cannabidiol: indima yamaqembu e-phenolic hydroxyl eqenjini le-resorcinol. ILife Sci 2011; 88 (15-16): 730-6. Buka okungaqondakali.
153. I-Yamaori S, i-Okamoto Y, i-Yamamoto I, i-Watanabe K. Cannabidiol, i-phytocannabinoid enkulu, njenge-inhibitor enamandla ye-CYP2D6. Izidakamizwa ze-Metab Dispos 2011; 39: 2049-56. Buka okungaqondakali.
154. I-Yamaori S, i-Maeda C, i-Yamamoto I, i-Watanabe K. Ukwahlukana okuhlukile kwe-cytochrome yomuntu i-P450 2A6 ne-2B6 ngama-phytocannabinoids amakhulu. I-Forensic Toxicol 2011; 29: 117-24.
155. I-Yamaori S, Kushihara M, Yamamoto I, Watanabe K. Ukuchazwa kwama-phytocannabinoids amakhulu, i-cannabidiol ne-cannabinol, njenge-isoform-selective potent inhibitors yama-enzyme e-CYP1 womuntu. I-Biochem Pharmacol 2010; 79: 1691-8. Buka okungaqondakali.
156. UZuardi AW, Crippa JA, Hallak JE, et al. I-Cannabidiol yokwelashwa kwengqondo ku-Parkinson's disease. UJ Psychopharmacol 2009; 23: 979-83. Buka okungaqondakali.
157. UMorgan CJ, uDas RK, uJoye A, et al. I-Cannabidiol inciphisa ukusetshenziswa kukagwayi kubantu ababhemayo kagwayi: ukutholwa kokuqala. Umlutha Behav 2013; 38: 2433-6. Buka okungaqondakali.
158. I-Pertwee RG. I-CB1 ne-CB2 receptor pharmacology yezitshalo ezintathu ze-cannabinoids: i-delta9-tetrahydrocannabinol, i-cannabidiol ne-delat9-tetrahydrocannabivarin. UBr J Pharmacol 2008; 153: 199-215. Buka okungaqondakali.
159. ILeweke FM, uKranaster L, uPahlisch F, et al. Ukusebenza kwe-cannabidiol ekwelapheni i-schizophrenia - indlela yokuhumusha. ISchizophr Bull 2011; 37 (iSuppl 1): 313.
160. ILeweke FM, uPiomelli D, uPahlisch F, et al. I-Cannabidiol ithuthukisa ukusayina kwe-anandamide futhi inciphise izimpawu zengqondo ze-schizophrenia. Humusha i-Psychiatry 2012; 2: e94. Buka okungaqondakali.
161. UCarroll CB, uBain PG, uTeare L, et al. I-Cannabis ye-dyskinesia esifo se-Parkinson: isifundo se-crossover esingaboni kahle. I-Neurology 2004; 63: 1245-50. Buka okungaqondakali.
162. IBergamaschi MM, iQueiroz RH, uChagas MH, et al. I-Cannabidiol inciphisa ukukhathazeka okubangelwa ukukhuluma komphakathi okufanisiwe kwiziguli zokwelashwa-na pve social phobia. I-Neuropsychopharmacology 2011; 36: 1219-26. Buka okungaqondakali.
163. UZuardi AW, Crippa JA, Hallak JE, et al. I-Cannabidiol, indawo ye-Cannabis sativa, njengesidakamizwa sokulwa ne-psychotic. I-Braz J Med Biol Res 2006; 39: 421-9. Buka okungaqondakali.
164. UYadav V, uBever C Jr, uBowen J, et al. Isifinyezo somhlahlandlela osuselwa ebufakazini: umuthi ohambisanayo kanye nokunye kwi-multiple sclerosis: umbiko wekomidi elincane lokuthuthukiswa komhlahlandlela weAmerican Academy of Neurology. Neurology. 2014; 82: 1083-92. Buka okungaqondakali.
165. UTrembly B, uSherman M. Ucwaningo lwemitholampilo engaboni kabili ye-cannabidiol njenge-anticonvulsant yesibili. Ingqungquthela Yomhlaba Wonke Yensangu ye-Marijuana '90 yeCannabis kanye ne-Cannabinoids 1990; 2: 5.
166. Srivastava, M. D., Srivastava, B. I., noBrouhard, B. Delta9 tetrahydrocannabinol kanye ne-cannabidiol bashintsha ukukhiqizwa kwe-cytokine ngamaseli omzimba womuntu. I-Immunopharmacology 1998; 40: 179-185. Buka okungaqondakali.
167. UCunha, JM, Carlini, EA, Pereira, AE, Ramos, OL, Pimentel, C., Gagliardi, R., Sanvito, WL, Lander, N., noMechoulam, R. Ukuphathwa okungapheli kwe-cannabidiol kumavolontiya anempilo kanye neziguli ezinesifo sokuwa . Ikhemisi 1980; 21: 175-185. Buka okungaqondakali.
168. UCarlini EA, uCunha JM. Imiphumela ye-hypnotic ne-antiepileptic ye-cannabidiol. UJ Clin Pharmacol 1981; 21 (8-9 Suppl): 417S-27S. Buka okungaqondakali.
169. UZuardi, A. W., Shirakawa, I., Finkelfarb, E., noKarniol, I. G. Isenzo se-cannabidiol ekukhathazeni nakweminye imiphumela eyenziwe yi-delta 9-THC ezifundweni ezijwayelekile. I-Psychopharmacology (Berl) 1982; 76: 245-250. Buka okungaqondakali.
170. Ames, F. R. noCridland, S. Umphumela we-Anticonvulsant we-cannabidiol. I-S.Afr.Med.J. 1-4-1986; 69:14. Buka okungaqondakali.
171. U-Ohlsson, A., Lindgren, J. E., Andersson, S., Agurell, S., Gillespie, H., noHollister, L. E. I-single-dose kinetics ye-deuterium enelebuli ye-cannabidiol kumuntu ngemuva kokubhema nokuphathwa kwemithambo. I-Biomed.Environ Mass Spectrom. 1986; 13: 77-83. Buka okungaqondakali.
172. UWade, D.T, uCollin, uC., UStott, uC, noDuncombe, uP. Meta-ukuhlaziywa kokusebenza nokuphepha kweSativex (nabiximols), ekuphakameni kwabantu abane-multiple sclerosis. I-Mult.Scler. 2010; 16: 707-714. Buka okungaqondakali.
173. UCollin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Novakova, I ., Zapletalova, O., Pikova, J., no-Ambler, Z. Ucwaningo lwe-Sativex oluyimpumputhe, olungenangqondo, olulawulwa yi-placebo, ngezihloko ezinezimpawu zokuphamba ngenxa ye-multiple sclerosis. Neurol.Res. 2010; 32: 451-459. Buka okungaqondakali.
174. UCrippa, J. A., Zuardi, A. W., Martin-Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., noFusar-Poli, P. Insangu nokukhathazeka: ukubuyekeza okubucayi kobufakazi. Hum. IPsychopharmacol. U-2009; 24: 515-523. Buka okungaqondakali.
175. Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., noSchram, K. Isivivinyo somtholampilo esilawulwayo se-cannabidiol kwisifo sikaHuntington. I-Pharmacol Biochem.I-Behav. 1991; 40: 701-708. Buka okungaqondakali.
176. UHarvey, D. J., Samara, E., noMechoulam, R. Ukuqhathanisa imetabolism ye-cannabidiol enjeni, egundaneni nasemuntwini. I-Pharmacol Biochem.I-Behav. 1991; 40: 523-532. Buka okungaqondakali.
177. UCollin, C., Davies, P., Mutiboko, I. K., noRatcliffe, S. Isivivinyo esilawulwa ngokungahleliwe semithi esuselwa ku-cannabis ekuphakameni okubangelwa yi-multiple sclerosis. U-Eur. J. Neurol. 2007; 14: 290-296. Buka okungaqondakali.
178. UMassi, P., Vaccani, A., Bianchessi, S., Costa, B., Macchi, P., noParolaro, D. I-cannabidiol engeyona eye-psychoactive ibangela ukwenziwa kwe-caspase kanye nengcindezi ye-oxidative kumaseli e-glioma womuntu. Iseli Mol. Life Sci. 2006; 63: 2057-2066. Buka okungaqondakali.
179. Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S., noGallily, R. Cannabidiol kwehlisa izehlakalo zesifo sikashukela kumagundane esifo sikashukela angakhuluphele. Ukuzimela okuzenzakalelayo 2006; 39: 143-151. Buka okungaqondakali.
180. I-Watzl, B., i-Scuderi, i-P, ne-Watson, i-R.R. Izakhi zensangu zikhuthaza uketshezi kwegazi lomzimba lenyukliya le-interferon-gamma kanye nokucindezela i-interleukin-1 alpha in vitro. I-Int J Immunopharmacol. 1991; 13: 1091-1097. Buka okungaqondakali.
181. I-Consroe, P., Kennedy, K., ne-Schram, K. Ukuhlolwa kwe-plasma cannabidiol nge-capillary gas chromatography / ion trap mass spectroscopy elandela ukuphathwa komlomo okuphindaphindwayo kwansuku zonke kubantu. I-Pharmacol Biochem.I-Behav. 1991; 40: 517-522. Buka okungaqondakali.
182. UBarnes, M. P. Sativex: ukusebenza komtholampilo nokubekezelela ekwelapheni izimpawu ze-multiple sclerosis nobuhlungu be-neuropathic. Isazi.Opin.I-Pharmacotherother. 2006; 7: 607-615. Buka okungaqondakali.
183. UWade, D.T, Makela, P., Robson, P., House, H., noBateman, C. Ingabe ukukhishwa okwenziwe nge-cannabis kwezokwelapha kunemiphumela ejwayelekile noma ethize kwizimpawu ze-multiple sclerosis? Ucwaningo olulawulwa kabili, olungahleliwe, olulawulwa yi-placebo ezigulini eziyi-160. I-Mult.Scler. 2004; 10: 434-441. Buka okungaqondakali.
184. Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., no-Izzo, umphumela we-AA Neuroprotective we-cannabidiol, ingxenye engeyona eyengqondo evela ku-Cannabis sativa, ku-beta-amyloid-eyenziwe ubuthi kumaseli we-PC12. J Neurochem. 2004; 89: 134-141. Buka okungaqondakali.
185. UMassi, P., Vaccani, A., Ceruti, S., Colombo, A., Abbracchio, M. P., noParolaro, D. Imiphumela ye-Antitumor ye-cannabidiol, i-cannabinoid engasebenzi, emigqeni yeseli ye-glioma. J Pharmacol Exp. Manje. 2004; 308: 838-845. Buka okungaqondakali.
186. UCrippa, JA, Zuardi, AW, Garrido, GE, Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, PM, Hallak, JE, McGuire, PK, noFoho, Busatto G. Imiphumela ye-cannabidiol (i-CBD) ekugelezeni kwegazi lobuchopho besifunda. I-Neuropsychopharmacology 2004; 29: 417-426. Buka okungaqondakali.
187. UWade, D.T., Robson, P., House, H., Makela, P., no-Aram, J. Ucwaningo lokuqala olulawulwayo lokuthola ukuthi ngabe ukukhishwa kwe-cannabis yesitshalo sonke kungathuthukisa yini izimpawu ze-neurogenic ezingenakulinganiswa. Umtholampilo Ukuvuselelwa. 2003; 17: 21-29. Buka okungaqondakali.
188. UCovington TR, et al. Incwajana Yezidakamizwa Ezingabhalisiwe. Umhla ka-11. IWashington, DC: I-American Pharmaceutical Association, 1996.

Kugcine ukubuyekezwa - 12/18/2020